Novel herbal compound offers potential to prevent and treat Alzheimer's disease

(IOS Press) Administration of the active compound tetrahydroxystilbene glucoside derived from the Chinese herbal medicine Polygonum multiflorum Thunb, reversed both overexpression of α-synuclein, a small protein found in the brain, and its accumulation using a mouse model of Alzheimer's disease. These results, which may shed light on the neuropathology of AD and open up new avenues of treatment, are available in the current issue of Restorative Neurology and Neuroscience.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news

Related Links:

Publication date: Available online 10 July 2020Source: International Review of NeurobiologyAuthor(s): Russell H. Swerdlow
Source: International Review of Neurobiology - Category: Neuroscience Source Type: research
Publication date: Available online 10 July 2020Source: International Review of NeurobiologyAuthor(s): Mark P. Mattson
Source: International Review of Neurobiology - Category: Neuroscience Source Type: research
A new multicenter trial has yielded conflicting results regarding intranasal insulin's ability to deliver cognitive and functional benefit in mild cognitive impairment and Alzheimer's disease.Medscape Medical News
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Psychiatry News Source Type: news
Condition:   MCI Interventions:   Dietary Supplement: Active group;   Dietary Supplement: Placebo group Sponsors:   Université de Sherbrooke;   Alzheimer Association;   Nestlé Health Science SA Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Will defining'dysexecutive'Alzheimer's disease lead to earlier diagnosis and better outcomes in this subtype? Editorial director Bret Stetka talks with Dr David Jones.Medscape Neurology
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery Expert Interview Source Type: news
Condition:   MCI Interventions:   Dietary Supplement: Active group;   Dietary Supplement: Placebo group Sponsors:   Université de Sherbrooke;   Alzheimer Association;   Nestlé Health Science SA Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
We report a new approach for the development of multitargeted therapeutics for Alzheimer ’s disease (AD) based on dual targeting of monomeric tau and biogenesis of microRNA-146a. Compound MG-1102 displayed superior... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chem. Commun. latest articles - Category: Chemistry Authors: Source Type: research
Introduction: Frontotemporal lobar degeneration (FTLD)-related syndrome includes progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). PSP is usually caused by a tauopathy but can have associated Alzheimer's disease (AD) while CBS can be caused by tauopathy, transactive response DNA binding protein 43 kDa, or AD pathology. Our aim was to compare the parkinsonian syndromes presenting without AD biomarkers (CBS/PSP-non-AD) to parkinsonian syndromes with AD biomarkers (CBS/PSP-AD).Materials and Methods: Twenty-four patients [11 males, 13 females; age (68.46 ± 7.23)] were recruited for this study. The wh...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
The objective of this study was to analyze the relationship between brain complexity and the presence of ApoE ε 4 alleles along the AD continuum. For this purpose, resting-state electroencephalography (EEG) activity was analyzed by computing Lempel-Ziv complexity (LZC) from 46 healthy control subjects, 49 mild cognitive impairment subjects, 45 mild AD patients, 44 moderate AD patients and 33 severe AD patients, subdivided by ApoE status. Subjects with one or more ApoE ε 4 alleles were included in the carriers subgroups, whereas the ApoE ε 4 non-carriers subgroups were formed by subjects ...
Source: Sensors - Category: Biotechnology Authors: Tags: Article Source Type: research
Alzheimer's disease (AD) is a very common neurodegenerative disorder, chiefly caused by increased production of neurotoxic β-amyloid (Aβ) peptide generated from proteolytic cleavage of β-amyloid protein precursor (APP). Except for familial AD arising from mutations in the APP and presenilin (PSEN) genes, the molecular mechanisms regulating the amyloidogenic processing of APP are largely unclear. Alcadein α/calsyntenin1 (ALCα/CLSTN1) is a neuronal type I transmembrane protein that forms a complex with APP, mediated by the neuronal adaptor protein X11-like (X11L or MINT2). Formation of the ALC&alph...
Source: Journal of Biological Chemistry - Category: Chemistry Authors: Tags: Molecular Bases of Disease Source Type: research
More News: Alzheimer's | Brain | Complementary Medicine | Fo-Ti | Health | Herbs | International Medicine & Public Health | Neurology